Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Studies of immune checkpoint therapy for cancer in 2019 uncovered critical insights into the differences between targeting CTLA4 versus PD1 and the role of particular T cell subsets in immune responses to cancer. Moreover, reverse translational studies are informing our understanding of resistance and response mechanisms in patients.
